GSA Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.36M | Buy |
4,702
+4,255
| +952% | +$2.04M | 0.15% | 110 |
|
|
2026
Q1 | $220K | Buy |
+447
| New | +$243K | 0.01% | 1412 |
|
|
2025
Q3 | – | Sell |
-3,794
| Closed | -$1.54M | – | 2093 |
|
|
2025
Q2 | $1.54M | Buy |
3,794
+2,332
| +160% | +$975K | 0.11% | 224 |
|
|
2025
Q1 | $727K | Sell |
1,462
-235
| -14% | -$127K | 0.07% | 544 |
|
|
2024
Q4 | $883K | Buy |
1,697
+680
| +67% | +$374K | 0.07% | 490 |
|
|
2024
Q3 | $629K | Sell |
1,017
-517
| -34% | -$306K | 0.05% | 763 |
|
|
2024
Q2 | $848K | Buy |
+1,534
| New | +$879K | 0.06% | 615 |
|
|
2024
Q1 | – | Sell |
-527
| Closed | -$280K | – | 1969 |
|
|
2023
Q4 | $280K | Buy |
+527
| New | +$255K | 0.02% | 1150 |
|
|
2023
Q3 | – | Sell |
-711
| Closed | -$371K | – | 1903 |
|
|
2023
Q2 | $371K | Buy |
711
+154
| +28% | +$83.1K | 0.04% | 922 |
|
|
2023
Q1 | $321K | Buy |
+557
| New | +$314K | 0.03% | 990 |
|
|
2021
Q2 | – | Sell |
-453
| Closed | -$207K | – | 1597 |
|
|
2021
Q1 | $207K | Buy |
+453
| New | +$216K | 0.03% | 882 |
|
|
2019
Q4 | – | Sell |
-723
| Closed | -$211K | – | 1730 |
|
|
2019
Q3 | $211K | Sell |
723
-62
| -8% | -$17.8K | 0.03% | 1148 |
|
|
2019
Q2 | $231K | Buy |
+785
| New | +$216K | 0.03% | 1168 |
|
|
2019
Q1 | – | Sell |
-8,028
| Closed | -$1.8M | – | 1698 |
|
|
2018
Q4 | $1.8M | Buy |
8,028
+6,475
| +417% | +$1.52M | 0.21% | 67 |
|
|
2018
Q3 | $379K | Sell |
1,553
-19,321
| -93% | -$4.44M | 0.02% | 1215 |
|
|
2018
Q2 | $4.32M | Buy |
20,874
+13,328
| +177% | +$2.83M | 0.21% | 42 |
|
|
2018
Q1 | $1.56M | Buy |
7,546
+6,312
| +512% | +$1.32M | 0.08% | 418 |
|
|
2017
Q4 | $234K | Buy |
+1,234
| New | +$236K | 0.01% | 1347 |
|
|
2017
Q3 | – | Sell |
-8,989
| Closed | -$1.57M | – | 1886 |
|
|
2017
Q2 | $1.57M | Sell |
8,989
-5,386
| -37% | -$905K | 0.1% | 259 |
|
|
2017
Q1 | $2.21M | Sell |
14,375
-17,842
| -55% | -$2.73M | 0.12% | 217 |
|
|
2016
Q4 | $4.55M | Buy |
32,217
+24,378
| +311% | +$3.59M | 0.27% | 21 |
|
|
2016
Q3 | $1.25M | Sell |
7,839
-13,445
| -63% | -$2.07M | 0.07% | 480 |
|
|
2016
Q2 | $3.15M | Buy |
21,284
+3,943
| +23% | +$582K | 0.17% | 90 |
|
|
2016
Q1 | $2.46M | Sell |
17,341
-492
| -3% | -$65.9K | 0.16% | 118 |
|
|
2015
Q4 | $2.53M | Buy |
+17,833
| New | +$2.38M | 0.12% | 174 |
|
|
2015
Q1 | – | Sell |
-11,275
| Closed | -$1.41M | – | 2208 |
|
|
2014
Q4 | $1.41M | Sell |
11,275
-1,333
| -11% | -$162K | 0.1% | 270 |
|
|
2014
Q3 | $1.53M | Sell |
12,608
-20,966
| -62% | -$2.55M | 0.08% | 287 |
|
|
2014
Q2 | $3.96M | Sell |
33,574
-17,829
| -35% | -$2.1M | 0.18% | 94 |
|
|
2014
Q1 | $6.18M | Buy |
+51,403
| New | +$6.11M | 0.44% | 27 |
|
|
2013
Q4 | – | Sell |
-15,502
| Closed | -$1.43M | – | 1767 |
|
|
2013
Q3 | $1.43M | Buy |
+15,502
| New | +$1.4M | 0.11% | 196 |
|
Other funds holding TMO
GSA Capital Partners's TMO Position: Q2 2026 in Review
GSA Capital Partners increased its Thermo Fisher Scientific (TMO) stake by 952% in Q2 2026, buying an estimated $2.04M and bringing the position to 4,702 shares worth $2.36M. The position accounts for 0.15% of the portfolio, ranked #110.
GSA Capital Partners first reported a position in TMO in Q3 2013 and has held it in 30 quarters since. The position peaked at $6.18M in Q1 2014. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- GSA Capital Partners held 4,702 shares of Thermo Fisher Scientific worth $2.36M as of Q2 2026.
- GSA Capital Partners bought 4,255 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.04M.
- Thermo Fisher Scientific made up 0.15% of GSA Capital Partners's portfolio in Q2 2026, its #110 holding.
- GSA Capital Partners first reported a position in Thermo Fisher Scientific in Q3 2013 and has held it in 30 quarters since.
- GSA Capital Partners's Thermo Fisher Scientific position peaked at $6.18M in Q1 2014.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.